Leland Gershell
Stock Analyst at Oppenheimer
(4.27)
# 1,360
Out of 4,456 analysts
760
Total ratings
40.6%
Success rate
8.1%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Reiterated: Buy | $1,014 | $887.18 | +14.29% | 17 | Jun 24, 2026 | |
| OKUR OnKure Therapeutics | Maintained: Buy | $30 | $4.50 | +566.67% | 1 | Jun 24, 2026 | |
| FULC Fulcrum Therapeutics | Rated: Hold | n/a | $3.80 | - | 1 | Jun 22, 2026 | |
| ENGN enGene Therapeutics | Rated: Hold | n/a | $1.75 | - | 8 | Jun 22, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Buy | $54 | $26.44 | +104.24% | 23 | Jun 18, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $262 | $260.75 | +0.48% | 37 | Jun 15, 2026 | |
| SABS SAB Biotherapeutics | Reiterated: Buy | $14 | $3.80 | +268.42% | 7 | Jun 15, 2026 | |
| SPRB Spruce Biosciences | Reiterated: Buy | $283 → $230 | $55.11 | +317.35% | 4 | May 27, 2026 | |
| TARA Protara Therapeutics | Reiterated: Buy | $25 → $28 | $4.12 | +579.61% | 21 | May 20, 2026 | |
| URGN UroGen Pharma | Reiterated: Buy | $40 | $34.54 | +15.81% | 46 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $3.05 | +129.51% | 2 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $0.8159 | +1,125.64% | 16 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $13.08 | +37.61% | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $87 → $84 | $36.70 | +128.88% | 19 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $18.15 | +32.23% | 17 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $31.50 | - | 34 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.50 | +566.67% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $17.90 | - | 34 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $4.75 | +321.05% | 3 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $162 → $277 | $303.59 | -8.76% | 2 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $21 | $4.79 | +338.41% | 2 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $3.01 | +730.56% | 44 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.39 | - | 7 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 | $38.85 | +39.00% | 8 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $100 | $0.9435 | +10,498.83% | 4 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $7.69 | +134.07% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $109.84 | - | 6 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $98 | $59.00 | +66.10% | 38 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $2.09 | +91.39% | 3 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $18.20 | +92.31% | 28 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $80 | $31.99 | +150.08% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $490 | $291.37 | +68.17% | 42 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $1.55 | n/a | 20 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $33.21 | n/a | 10 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $106 | $82.19 | n/a | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $0.8885 | n/a | 19 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.02 | n/a | 17 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $1.24 | n/a | 19 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.38 | n/a | 16 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $6.06 | n/a | 6 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $0.13 | n/a | 11 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 → $200 | $0.000001 | n/a | 11 | Mar 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $8.74 | n/a | 16 | Nov 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $0.014 | n/a | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $12 | $0.28 | n/a | 11 | Jun 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 | $0.7701 | n/a | 16 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $1.59 | n/a | 7 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.0015 | n/a | 4 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $15.91 | n/a | 13 | Dec 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.75 | n/a | 22 | Dec 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.71 | n/a | 9 | Dec 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0082 | n/a | 15 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.898 | n/a | 3 | May 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.03 | n/a | 9 | May 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $4.41 | n/a | 9 | Apr 3, 2019 |
argenx SE
Jun 24, 2026
Reiterated: Buy
Price Target: $1,014
Current: $887.18
Upside: +14.29%
OnKure Therapeutics
Jun 24, 2026
Maintained: Buy
Price Target: $30
Current: $4.50
Upside: +566.67%
Fulcrum Therapeutics
Jun 22, 2026
Rated: Hold
Price Target: n/a
Current: $3.80
Upside: -
enGene Therapeutics
Jun 22, 2026
Rated: Hold
Price Target: n/a
Current: $1.75
Upside: -
Capricor Therapeutics
Jun 18, 2026
Reiterated: Buy
Price Target: $54
Current: $26.44
Upside: +104.24%
Ascendis Pharma
Jun 15, 2026
Reiterated: Buy
Price Target: $262
Current: $260.75
Upside: +0.48%
SAB Biotherapeutics
Jun 15, 2026
Reiterated: Buy
Price Target: $14
Current: $3.80
Upside: +268.42%
Spruce Biosciences
May 27, 2026
Reiterated: Buy
Price Target: $283 → $230
Current: $55.11
Upside: +317.35%
Protara Therapeutics
May 20, 2026
Reiterated: Buy
Price Target: $25 → $28
Current: $4.12
Upside: +579.61%
UroGen Pharma
May 19, 2026
Reiterated: Buy
Price Target: $40
Current: $34.54
Upside: +15.81%
May 15, 2026
Reiterated: Buy
Price Target: $7
Current: $3.05
Upside: +129.51%
May 15, 2026
Reiterated: Buy
Price Target: $10
Current: $0.8159
Upside: +1,125.64%
May 15, 2026
Reiterated: Buy
Price Target: $18
Current: $13.08
Upside: +37.61%
May 11, 2026
Maintained: Buy
Price Target: $87 → $84
Current: $36.70
Upside: +128.88%
May 8, 2026
Reiterated: Buy
Price Target: $24
Current: $18.15
Upside: +32.23%
May 7, 2026
Downgraded: Hold
Price Target: n/a
Current: $31.50
Upside: -
May 6, 2026
Reiterated: Buy
Price Target: $10
Current: $1.50
Upside: +566.67%
Apr 13, 2026
Rated: Hold
Price Target: n/a
Current: $17.90
Upside: -
Mar 31, 2026
Reiterated: Buy
Price Target: $20
Current: $4.75
Upside: +321.05%
Feb 27, 2026
Maintained: Buy
Price Target: $162 → $277
Current: $303.59
Upside: -8.76%
Feb 27, 2026
Maintained: Buy
Price Target: $35 → $21
Current: $4.79
Upside: +338.41%
Feb 12, 2026
Reiterated: Buy
Price Target: $25
Current: $3.01
Upside: +730.56%
Feb 10, 2026
Rated: Hold
Price Target: n/a
Current: $25.39
Upside: -
Feb 9, 2026
Maintained: Buy
Price Target: $54
Current: $38.85
Upside: +39.00%
Nov 14, 2025
Maintained: Buy
Price Target: $100
Current: $0.9435
Upside: +10,498.83%
Nov 7, 2025
Maintained: Buy
Price Target: $18
Current: $7.69
Upside: +134.07%
Nov 4, 2025
Downgraded: Hold
Price Target: n/a
Current: $109.84
Upside: -
Oct 28, 2025
Reiterated: Buy
Price Target: $98
Current: $59.00
Upside: +66.10%
Oct 14, 2025
Reiterated: Buy
Price Target: $4
Current: $2.09
Upside: +91.39%
Sep 29, 2025
Reiterated: Buy
Price Target: $35
Current: $18.20
Upside: +92.31%
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $80
Current: $31.99
Upside: +150.08%
Aug 4, 2025
Upgraded: Buy
Price Target: $490
Current: $291.37
Upside: +68.17%
Sep 16, 2024
Maintained: Buy
Price Target: $25
Current: $1.55
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $33.21
Upside: n/a
May 14, 2024
Maintained: Buy
Price Target: $106
Current: $82.19
Upside: n/a
Mar 28, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $0.8885
Upside: n/a
Dec 18, 2023
Maintained: Buy
Price Target: n/a
Current: $4.02
Upside: n/a
Nov 13, 2023
Maintained: Buy
Price Target: $11
Current: $1.24
Upside: n/a
Jul 10, 2023
Maintained: Buy
Price Target: n/a
Current: $2.38
Upside: n/a
Oct 4, 2022
Downgraded: Hold
Price Target: n/a
Current: $6.06
Upside: n/a
May 26, 2022
Maintained: Buy
Price Target: $60
Current: $0.13
Upside: n/a
Mar 21, 2022
Maintained: Buy
Price Target: $70 → $200
Current: $0.000001
Upside: n/a
Nov 16, 2021
Reiterated: Hold
Price Target: n/a
Current: $8.74
Upside: n/a
Jun 4, 2021
Initiated Coverage: Buy
Price Target: $8
Current: $0.014
Upside: n/a
Jun 2, 2021
Rated: Buy
Price Target: $12
Current: $0.28
Upside: n/a
May 18, 2021
Rated: Buy
Price Target: $7
Current: $0.7701
Upside: n/a
May 7, 2021
Initiated Coverage: Buy
Price Target: $42
Current: $1.59
Upside: n/a
May 6, 2021
Maintained: Hold
Price Target: n/a
Current: $0.0015
Upside: n/a
Dec 31, 2020
Rated: Hold
Price Target: n/a
Current: $15.91
Upside: n/a
Dec 31, 2020
Rated: Hold
Price Target: n/a
Current: $8.75
Upside: n/a
Dec 31, 2020
Rated: Hold
Price Target: n/a
Current: $1.71
Upside: n/a
Sep 11, 2020
Rated: Hold
Price Target: n/a
Current: $0.0082
Upside: n/a
May 10, 2019
Reiterated: Buy
Price Target: $7
Current: $0.898
Upside: n/a
May 9, 2019
Rated: Hold
Price Target: n/a
Current: $1.03
Upside: n/a
Apr 3, 2019
Reiterated: Buy
Price Target: $8
Current: $4.41
Upside: n/a